Attorney Docket No.: Q74006

SUPPLEMENTAL AMENDMENT

Application No.: 10/764,553

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the

application:

LISTING OF CLAIMS:

1-12. (canceled)

13. (withdrawn-previously presented): A method of preparing the Mycobacterium

promoter of claim 23, said process comprising the steps of:

(a) isolating said promoter from Mycobacterium DNA,

(b) ligating the isolated promoter sequence of step (a) into a plasmid vector.

14. (withdrawn-previously presented): The process of claim 13, wherein the

Mycohacterium promoter is 2.5 fold more active in M. Smegmatis than the heat shock protein

promoter (Phsp60).

15. (withdrawn-previously presented): A process of expressing a reporter gene in M.

smegmatis under carbon starved conditions, the process comprising the step of growing M.

smegmatis containing the promoter of claim 28, wherein the carbon source is about 2.5 to

0.001% glucose.

16. (withdrawn-previously presented): The process of claim 15, wherein the carbon

source is about 2 to 0.02% glucose.

2

SUPPLEMENTAL AMENDMENT Attorney Docket No.: Q74006

Application No.: 10/764,553

17. (withdrawn-previously presented): The process of claim 15, wherein the growth of

the M. smegmatis is reduced by about 6 to 25% by the presence of ethambutol.

18. (withdrawn-previously presented): The process of claim 17, wherein the growth of

the M. smegmatis is reduced by about 7 to 21% by the presence of ethambutol.

19. (withdrawn-previously presented): The process of claim 15, wherein the growth of

the M smegmatis is reduced by about 15 to 45% by the presence of isoniazid.

20. (withdrawn-previously presented): The process of claim 19, wherein the growth of

the M. smegmatis is reduced by about 18 to 40 % in the presence of isoniazid.

21. (withdrawn-previously presented): The process of claim 15, wherein the growth of

the M. smegmatis is reduced by about 20 to 45% by the presence of rifampicin.

22. (withdrawn-previously presented): The process of claim 21, wherein the growth of

the M. smegmatis is reduced by about 21 to 41% by the presence of rifamipicin.

23. (currently amended): A Mycobacterium promoter, wherein the promoter is stable

in M. smegmatis and E. coli, and consists essentially of a 200 base pair fragment upstream and

proximal to the Mycobacterium tuberculosis relA/SpoT gene.

3

Attorney Docket No.: Q74006

SUPPLEMENTAL AMENDMENT Application No.: 10/764,553

24. (previously presented): The *Mycobacterium* promoter of claim 23, wherein the promoter is operatively linked to a reporter gene.

 (previously presented): The Mycobacterium promoter of claim 24, wherein said reporter gene is LacZ.

26. (previously presented): The Mycobacterium promoter of claim 24, wherein said reporter gene is xylE.

27. (currently amended): The Mycobacterium promoter of claim 24, wherein the promoter is 2.5 fold more active in M. smegmatis than -a heat shock protein 60 promoter, Phsp60.

28 (previously presented): The *Mycobacterium* promoter of claim 24, wherein the promoter is further contained in a plasmid with an Ampicillin or Kanamycin resistance marker.

29. (previously presented): The *Mycobacterium* promoter of claim 23, wherein the promoter consists of SEQ ID NO:2.

30. (canceled).